APO Research
Talk to an analyst

APO RESEARCH · REPORT

End-Stage Renal Disease (ESRD) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global End-Stage Renal Disease (ESRD) Drugs Market Analysis and Forecast 2026-2032

19 December 2025192 pages

Choose your research edition.

Industry ResearchEnd-Stage Renal Disease (ESRD) Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal End-Stage Renal Disease (ESRD) Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal End-Stage Renal Disease (ESRD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal End-Stage Renal Disease (ESRD) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal End-Stage Renal Disease (ESRD) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global End-Stage Renal Disease (ESRD) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for End-Stage Renal Disease (ESRD) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for End-Stage Renal Disease (ESRD) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for End-Stage Renal Disease (ESRD) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for End-Stage Renal Disease (ESRD) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of End-Stage Renal Disease (ESRD) Drugs include Novartis AG, Merck & Co Inc, VESSL Therapeutics Ltd, Prolong Pharmaceuticals LLC and CTI BioPharma Corp, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for End-Stage Renal Disease (ESRD) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of End-Stage Renal Disease (ESRD) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for End-Stage Renal Disease (ESRD) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the End-Stage Renal Disease (ESRD) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global End-Stage Renal Disease (ESRD) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for End-Stage Renal Disease (ESRD) Drugs sales, projected growth trends, production technology, application and end-user industry.

End-Stage Renal Disease (ESRD) Drugs Segment by Company

Novartis AG

Merck & Co Inc

VESSL Therapeutics Ltd

Prolong Pharmaceuticals LLC

CTI BioPharma Corp

End-Stage Renal Disease (ESRD) Drugs Segment by Type

Sanguinate

Tesidolumab

Calcium Succinate

Mk-3866

Pacritinib

Others

End-Stage Renal Disease (ESRD) Drugs Segment by Application

ICU

Hospital

Clinic

Others

End-Stage Renal Disease (ESRD) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End-Stage Renal Disease (ESRD) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of End-Stage Renal Disease (ESRD) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End-Stage Renal Disease (ESRD) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of End-Stage Renal Disease (ESRD) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of End-Stage Renal Disease (ESRD) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, End-Stage Renal Disease (ESRD) Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global End-Stage Renal Disease (ESRD) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Sanguinate Major Manufacturers Table 3. Tesidolumab Major Manufacturers Table 4. Calcium Succinate Major Manufacturers Table 5. Mk-3866 Major Manufacturers Table 6. Pacritinib Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global End-Stage Renal Disease (ESRD) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. ICU Major Manufacturers Table 10. Hospital Major Manufacturers Table 11. Clinic Major Manufacturers Table 12. Others Major Manufacturers Table 13. End-Stage Renal Disease (ESRD) Drugs Industry Trends Table 14. End-Stage Renal Disease (ESRD) Drugs Industry Drivers Table 15. End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges Table 16. End-Stage Renal Disease (ESRD) Drugs Industry Restraints Table 17. Global End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 19. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 20. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2021-2026) Table 21. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2027-2032) Table 22. Global End-Stage Renal Disease (ESRD) Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 23. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2026) & (K Units) Table 24. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2027-2032) & (K Units) Table 25. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2021-2026) Table 26. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2027-2032) Table 27. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 29. Global End-Stage Renal Disease (ESRD) Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers (2021-2026) Table 31. Global End-Stage Renal Disease (ESRD) Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global End-Stage Renal Disease (ESRD) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global End-Stage Renal Disease (ESRD) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global End-Stage Renal Disease (ESRD) Drugs Manufacturers, Product Type & Application Table 35. Global End-Stage Renal Disease (ESRD) Drugs Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global End-Stage Renal Disease (ESRD) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 40. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 41. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2026) Table 42. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2027-2032) Table 43. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 44. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 45. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 46. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2026) Table 47. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2027-2032) Table 48. Global End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2026) & (US$/Unit) Table 49. Global End-Stage Renal Disease (ESRD) Drugs Price by Type (2027-2032) & (US$/Unit) Table 50. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 52. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 53. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2026) Table 54. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2027-2032) Table 55. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 56. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 57. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2026) Table 59. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2027-2032) Table 60. Global End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2026) & (US$/Unit) Table 61. Global End-Stage Renal Disease (ESRD) Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. Novartis AG Company Information Table 63. Novartis AG Business Overview Table 64. Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 66. Novartis AG Recent Development Table 67. Merck & Co Inc Company Information Table 68. Merck & Co Inc Business Overview Table 69. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 71. Merck & Co Inc Recent Development Table 72. VESSL Therapeutics Ltd Company Information Table 73. VESSL Therapeutics Ltd Business Overview Table 74. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 76. VESSL Therapeutics Ltd Recent Development Table 77. Prolong Pharmaceuticals LLC Company Information Table 78. Prolong Pharmaceuticals LLC Business Overview Table 79. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 81. Prolong Pharmaceuticals LLC Recent Development Table 82. CTI BioPharma Corp Company Information Table 83. CTI BioPharma Corp Business Overview Table 84. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 86. CTI BioPharma Corp Recent Development Table 87. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 88. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 89. North America End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 90. North America End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 91. North America End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 92. North America End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 93. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 94. North America End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 95. North America End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 96. North America End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 97. North America End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 98. North America End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 99. North America End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 101. North America End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 102. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 103. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 104. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 105. North America End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 106. North America End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 107. United States End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 108. Canada End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 109. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 112. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 113. Europe End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 114. Europe End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 115. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 118. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 119. Europe End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 120. Europe End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 121. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 123. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 124. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 125. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 126. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 127. Europe End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 128. Europe End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 129. Germany End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 130. France End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 131. U.K. End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 132. Italy End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 133. Netherlands End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 134. China End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. China End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. China End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 137. China End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 138. China End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 139. China End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 140. China End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 141. China End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 142. China End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 143. China End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 144. China End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 145. China End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 146. Asia End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. Asia End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 149. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 150. Asia End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 151. Asia End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 152. Asia End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 155. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 156. Asia End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 157. Asia End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 158. Asia End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. Asia End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 162. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 163. Asia End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 164. Asia End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 165. Asia End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 166. Japan End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 167. South Korea End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 168. India End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 169. Australia End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 170. China Taiwan End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 171. Southeast Asia End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 172. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 173. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 174. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 175. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 176. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 177. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 178. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 181. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 182. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 183. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 184. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 188. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 189. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 190. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 191. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 192. Brazil End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 193. Argentina End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 194. Chile End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 195. Colombia End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 196. Peru End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 197. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 198. Israel End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 199. UAE End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 200. Turkey End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 201. Iran End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 202. Egypt End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. End-Stage Renal Disease (ESRD) Drugs Distributors List Table 206. End-Stage Renal Disease (ESRD) Drugs Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. End-Stage Renal Disease (ESRD) Drugs Image Figure 2. Global End-Stage Renal Disease (ESRD) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global End-Stage Renal Disease (ESRD) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Sanguinate Image Figure 5. Tesidolumab Image Figure 6. Calcium Succinate Image Figure 7. Mk-3866 Image Figure 8. Pacritinib Image Figure 9. Others Image Figure 10. Global End-Stage Renal Disease (ESRD) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global End-Stage Renal Disease (ESRD) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 12. ICU Image Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Others Image Figure 16. Global End-Stage Renal Disease (ESRD) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Figure 18. Global End-Stage Renal Disease (ESRD) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2021-2032) Figure 21. Global End-Stage Renal Disease (ESRD) Drugs Sales (2021-2032) & (K Units) Figure 22. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 23. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico End-Stage Renal Disease (ESRD) Drugs Sales YoY (2021-2032) & (K Units) Figure 25. Europe End-Stage Renal Disease (ESRD) Drugs Sales YoY (2021-2032) & (K Units) Figure 26. China End-Stage Renal Disease (ESRD) Drugs Sales YoY (2021-2032) & (K Units) Figure 27. Asia (Excluding China) End-Stage Renal Disease (ESRD) Drugs Sales YoY (2021-2032) & (K Units) Figure 28. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales YoY (2021-2032) & (K Units) Figure 29. Global End-Stage Renal Disease (ESRD) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global End-Stage Renal Disease (ESRD) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2032) Figure 35. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2032) Figure 38. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2032) Figure 41. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 42. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2032) Figure 44. North America End-Stage Renal Disease (ESRD) Drugs Revenue Share by Type (2021-2032) Figure 45. North America End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2021-2032) Figure 46. North America End-Stage Renal Disease (ESRD) Drugs Revenue Share by Application (2021-2032) Figure 47. North America End-Stage Renal Disease (ESRD) Drugs Sales Share by Application (2021-2032) Figure 48. North America End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country (2021-2032) Figure 49. North America End-Stage Renal Disease (ESRD) Drugs Sales Share by Country (2021-2032) Figure 50. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Share by Type (2021-2032) Figure 51. Europe End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2021-2032) Figure 52. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Share by Application (2021-2032) Figure 53. Europe End-Stage Renal Disease (ESRD) Drugs Sales Share by Application (2021-2032) Figure 54. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country (2021-2032) Figure 55. Europe End-Stage Renal Disease (ESRD) Drugs Sales Share by Country (2021-2032) Figure 56. China End-Stage Renal Disease (ESRD) Drugs Revenue Share by Type (2021-2032) Figure 57. China End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2021-2032) Figure 58. China End-Stage Renal Disease (ESRD) Drugs Revenue Share by Application (2021-2032) Figure 59. China End-Stage Renal Disease (ESRD) Drugs Sales Share by Application (2021-2032) Figure 60. Asia End-Stage Renal Disease (ESRD) Drugs Revenue Share by Type (2021-2032) Figure 61. Asia End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2021-2032) Figure 62. Asia End-Stage Renal Disease (ESRD) Drugs Revenue Share by Application (2021-2032) Figure 63. Asia End-Stage Renal Disease (ESRD) Drugs Sales Share by Application (2021-2032) Figure 64. Asia End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country (2021-2032) Figure 65. Asia End-Stage Renal Disease (ESRD) Drugs Sales Share by Country (2021-2032) Figure 66. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Share by Type (2021-2032) Figure 67. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2021-2032) Figure 68. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Share by Application (2021-2032) Figure 69. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Share by Application (2021-2032) Figure 70. SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country (2021-2032) Figure 71. SAMEA End-Stage Renal Disease (ESRD) Drugs Sales Share by Country (2021-2032) Figure 72. End-Stage Renal Disease (ESRD) Drugs Value Chain Figure 73. Manufacturing Cost Structure Figure 74. End-Stage Renal Disease (ESRD) Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Sanguinate
  • Tesidolumab
  • Calcium Succinate
  • Mk-3866
  • Pacritinib
  • Others
Applications
  • ICU
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co Inc
  • VESSL Therapeutics Ltd
  • Prolong Pharmaceuticals LLC
  • CTI BioPharma Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 End-Stage Renal Disease (ESRD) Drugs Market by Type
  3. 1.2.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Sanguinate
  5. 1.2.3 Tesidolumab
  6. 1.2.4 Calcium Succinate
  7. 1.2.5 Mk-3866
  8. 1.2.6 Pacritinib
  9. 1.2.7 Others
  10. 1.3 End-Stage Renal Disease (ESRD) Drugs Market by Application
  11. 1.3.1 Global End-Stage Renal Disease (ESRD) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 ICU
  13. 1.3.3 Hospital
  14. 1.3.4 Clinic
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 End-Stage Renal Disease (ESRD) Drugs Market Dynamics
  1. 2.1 End-Stage Renal Disease (ESRD) Drugs Industry Trends
  2. 2.2 End-Stage Renal Disease (ESRD) Drugs Industry Drivers
  3. 2.3 End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges
  4. 2.4 End-Stage Renal Disease (ESRD) Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region
  3. 3.2.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region
  9. 3.4.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Manufacturers
  2. 4.1.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global End-Stage Renal Disease (ESRD) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Manufacturers
  6. 4.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global End-Stage Renal Disease (ESRD) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global End-Stage Renal Disease (ESRD) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global End-Stage Renal Disease (ESRD) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global End-Stage Renal Disease (ESRD) Drugs Manufacturers, Product Type & Application
  13. 4.7 Global End-Stage Renal Disease (ESRD) Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global End-Stage Renal Disease (ESRD) Drugs Market CR5 and HHI
  16. 4.8.2 2025 End-Stage Renal Disease (ESRD) Drugs Tier 1, Tier 2, and Tier 3
5 End-Stage Renal Disease (ESRD) Drugs Market by Type
  1. 5.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type
  2. 5.1.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type
  6. 5.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Type
6 End-Stage Renal Disease (ESRD) Drugs Market by Application
  1. 6.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application
  2. 6.1.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application
  6. 6.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global End-Stage Renal Disease (ESRD) Drugs Price by Application
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Merck & Co Inc
  8. 7.2.1 Merck & Co Inc Company Information
  9. 7.2.2 Merck & Co Inc Business Overview
  10. 7.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  12. 7.2.5 Merck & Co Inc Recent Developments
  13. 7.3 VESSL Therapeutics Ltd
  14. 7.3.1 VESSL Therapeutics Ltd Company Information
  15. 7.3.2 VESSL Therapeutics Ltd Business Overview
  16. 7.3.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  18. 7.3.5 VESSL Therapeutics Ltd Recent Developments
  19. 7.4 Prolong Pharmaceuticals LLC
  20. 7.4.1 Prolong Pharmaceuticals LLC Company Information
  21. 7.4.2 Prolong Pharmaceuticals LLC Business Overview
  22. 7.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  24. 7.4.5 Prolong Pharmaceuticals LLC Recent Developments
  25. 7.5 CTI BioPharma Corp
  26. 7.5.1 CTI BioPharma Corp Company Information
  27. 7.5.2 CTI BioPharma Corp Business Overview
  28. 7.5.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  30. 7.5.5 CTI BioPharma Corp Recent Developments
8 North America
  1. 8.1 North America End-Stage Renal Disease (ESRD) Drugs Market Size by Type
  2. 8.1.1 North America End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2032)
  5. 8.2 North America End-Stage Renal Disease (ESRD) Drugs Market Size by Application
  6. 8.2.1 North America End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2032)
  9. 8.3 North America End-Stage Renal Disease (ESRD) Drugs Market Size by Country
  10. 8.3.1 North America End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America End-Stage Renal Disease (ESRD) Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe End-Stage Renal Disease (ESRD) Drugs Market Size by Type
  2. 9.1.1 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2032)
  5. 9.2 Europe End-Stage Renal Disease (ESRD) Drugs Market Size by Application
  6. 9.2.1 Europe End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2032)
  9. 9.3 Europe End-Stage Renal Disease (ESRD) Drugs Market Size by Country
  10. 9.3.1 Europe End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe End-Stage Renal Disease (ESRD) Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China End-Stage Renal Disease (ESRD) Drugs Market Size by Type
  2. 10.1.1 China End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
  4. 10.1.3 China End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2032)
  5. 10.2 China End-Stage Renal Disease (ESRD) Drugs Market Size by Application
  6. 10.2.1 China End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
  8. 10.2.3 China End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia End-Stage Renal Disease (ESRD) Drugs Market Size by Type
  2. 11.1.1 Asia End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2032)
  5. 11.2 Asia End-Stage Renal Disease (ESRD) Drugs Market Size by Application
  6. 11.2.1 Asia End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2032)
  9. 11.3 Asia End-Stage Renal Disease (ESRD) Drugs Market Size by Country
  10. 11.3.1 Asia End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia End-Stage Renal Disease (ESRD) Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA End-Stage Renal Disease (ESRD) Drugs Market Size by Type
  2. 12.1.1 SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA End-Stage Renal Disease (ESRD) Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA End-Stage Renal Disease (ESRD) Drugs Market Size by Application
  6. 12.2.1 SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA End-Stage Renal Disease (ESRD) Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA End-Stage Renal Disease (ESRD) Drugs Market Size by Country
  10. 12.3.1 SAMEA End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA End-Stage Renal Disease (ESRD) Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 End-Stage Renal Disease (ESRD) Drugs Value Chain Analysis
  2. 13.1.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 End-Stage Renal Disease (ESRD) Drugs Production Mode & Process
  6. 13.2 End-Stage Renal Disease (ESRD) Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 End-Stage Renal Disease (ESRD) Drugs Distributors
  9. 13.2.3 End-Stage Renal Disease (ESRD) Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst